Drug Trial Radar · NCT05176483
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
Last checked: Nov 19, 2026Latest source record: Oct 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
1,394
Planned (sponsor's estimate)
Start
Dec 14, 2021
Primary completion
Jan 31, 2027
Study completion Jun 28, 2030
Sponsor
- Lead sponsor
- ExelixisIndustry
- Sponsor type
- Industry
- First posted
- Jan 4, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter Phase 1b, open label, dose-escalation and cohort-expansion study, evaluating the safety, tolerability, pharmacokinetics (PK), preliminary antitumor activity, and effect of biomarkers of zanzalintinib administered alone, and in combination with nivolumab (doublet), nivolumab + ipilimumab (triplet) and nivolumab + relatlimab (triplet) and in combination with docetaxel and prednisone in participants with advanced solid tumors. In addition, the study will evaluate the effect of multiple dose administration of zanzalintinib on the single-dose pharmacokinetics of sensitive CYP3A4, CYP2C9, CYP2C19, or CYP1A2 substrates in participants with advanced solid tumors. In the Expansion Stage, the safety and efficacy of zanzalintinib as monotherapy and in combination therapy will be further evaluated in tumor-specific Expansion Cohorts.
Conditions
- Renal Cell Carcinoma (RCC)
- Metastatic Castration-Resistant Prostate Cancer (mCRPC)
- Urothelial Carcinoma (UC)
- Solid Tumor
- Hepatocellular Carcinoma (HCC)
- Non-small Cell Lung Cancer (NSCLC)
- Colorectal Cancer (CRC)
- Head and Neck Squamous Cell Carcinoma (HNSCC)
- Clear Cell Renal Cell Carcinoma (ccRCC)
- Non-Clear Cell Renal Cell Carcinoma (nccRCC)
- Drug-Drug Interaction (DDI)
Interventions
ZanzalintinibDrug
Zanzalintinib orally once daily (qd)
NivolumabDrug
360 mg intravenous (IV) infusion once every 3 weeks (q3w)
IpilimumabDrug
1 mg/kg IV infusion once every 3 weeks (q3w) for maximum of four doses
Nivolumab + RelatlimabDrug
IV administration of nivolumab + relatlimab
PrednisoneDrug
Administered as IV infusion.
DocetaxelDrug
Administered as oral tablet.
DDI Probe CocktailDrug
Midazolam, Warfarin, Omeprazole, and Caffeine administered orally.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs), Including Immune-Mediated Adverse Events (imAEs)Time frame: Up to 36 months
- Expansion Stage (All Cohorts Except Cohort 15 [mCRPC, post-ARPI, visceral metastases] and Cohort 16 [DDI]): Objective Response Rate (ORR)Time frame: Up to 24 months
- Expansion Stage Cohort 3 (mCRPC, post 1 NHT): Progression-Free Survival (PFS)Time frame: Up to 24 months
- Expansion Stage Cohort 10 (CRC): Overall Survival (OS)Time frame: 6 months
- Expansion Stage Cohort 15 (mCRPC, Post-ARPI, Visceral Metastases): PFS-6 (Six Month PFS)Time frame: 6 months
- Expansion Stage Cohort 16 (DDI): Area Under the Concentration-Versus-Time Curve (AUC) of Each DDI Probe Substrate With and Without ZanzalintinibTime frame: Predose upto 8 hours postdose
- Expansion Stage Cohort 16 (DDI): Maximum Concentration (Cmax) of Each DDI Probe Substrate With and Without ZanzalintinibTime frame: Predose upto 8 hours postdose
Locations
122 sites in 13 countries. Site status is shown where the registry gives one.
Exelixis Clinical Site #67
Phoenix, Arizona · Recruiting
Exelixis Clinical Site #1
Tucson, Arizona · Recruiting
Exelixis Clinical Site #123
Palo Alto, California · Completed
Exelixis Clinical Site #59
Santa Barbara, California · Recruiting
Exelixis Clinical Site #87
Littleton, Colorado · Recruiting
Exelixis Clinical Site #62
New Haven, Connecticut · Recruiting
Exelixis Clinical Site #49
Newark, Delaware · Active not recruiting
Exelixis Clinical Site #48
Celebration, Florida · Recruiting
Exelixis Clinical Site #11
Gainesville, Florida · Recruiting
Exelixis Clinical Site #78
Jacksonville, Florida · Recruiting
Exelixis Clinical Site #47
Miami, Florida · Recruiting
Exelixis Clinical Site #61
Plantation, Florida · Withdrawn
Exelixis Clinical Site #8
Tampa, Florida · Recruiting
Exelixis Clinical Site #26
Chicago, Illinois · Recruiting
Exelixis Clinical Site #4
Indianapolis, Indiana · Recruiting
Exelixis Clinical Site #122
Louisville, Kentucky · Withdrawn
Exelixis Clinical Site #14
Baltimore, Maryland · Recruiting
Exelixis Clinical Site #7
Boston, Massachusetts · Recruiting
Exelixis Clinical Site #65
Detroit, Michigan · Recruiting
Exelixis Clinical Site #13
Detroit, Michigan · Recruiting
Exelixis Clinical Site #68
Rochester, Minnesota · Recruiting
Exelixis Clinical Site #2
Omaha, Nebraska · Recruiting
Exelixis Clinical Site #5
Omaha, Nebraska · Active not recruiting
Exelixis Clinical Site #55
Las Vegas, Nevada · Recruiting
Exelixis Clinical Site #88
East Brunswick, New Jersey · Recruiting
Exelixis Clinical Site #105
Hackensack, New Jersey · Recruiting
Exelixis Clinical Site #60
New York, New York · Recruiting
Exelixis Clinical Site #6
New York, New York · Recruiting
Exelixis Clinical Site #76
Syracuse, New York · Recruiting
Exelixis Clinical Site #12
Durham, North Carolina · Recruiting
Exelixis Clinical Site #10
Cleveland, Ohio · Recruiting
Exelixis Clinical Site #51
Portland, Oregon · Recruiting
Exelixis Clinical Site #104
Hershey, Pennsylvania · Recruiting
Exelixis Clinical Site #98
Philadelphia, Pennsylvania · Recruiting
Exelixis Clinical Site #32
Pittsburgh, Pennsylvania · Recruiting
Exelixis Clinical Site #24
Pittsburgh, Pennsylvania · Completed
Exelixis Clinical Site #9
Myrtle Beach, South Carolina · Recruiting
Exelixis Clinical Site #3
Nashville, Tennessee · Recruiting
Exelixis Clinical Site #46
Austin, Texas · Recruiting
Exelixis Clinical Site #111
Dallas, Texas · Withdrawn
Showing 40 of 122 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.